Background {#Sec1}
==========

Vascular dementia is a serious consequence of diabetes \[[@CR1]\]. Prolonged exposure to high blood levels of glucose, typical of type 2 diabetes, affects capillary endothelial structure, function and permeability \[[@CR2]\]. Failure in the blood brain barrier lies at the foundation of cerebral small vessel disease and contributes to the pathogenesis of diabetic encephalopathy \[[@CR3]\] Methods for in vivo quantification and localization of changes in blood--brain barrier permeability are needed to understand and diagnose the early onset of vascular dementia with type 2 diabetes.

Imaging the subtle changes in blood--brain permeability is not possible with standard imaging protocols but can be assessed with dynamic contrast enhanced (DCE) MRI \[[@CR4]\]. However, dynamic contrast enhanced MRI has several limitations. The concentration versus time curve for gadolinium-based contrast agent is typically 15--30% inaccurate; therefore, DCE-MRI has not proven useful clinically \[[@CR5]\]. It is also difficult to model the effects of contrast agent on both T2\* and T1 given the short acquisition time, and strong dependence on microstructural properties such as vessel size, tortuosity and orientation. These and other methodological issues with the use of DCE-MRI for blood--brain barrier permeability have resulted in significant differences in the reported rates of leakage \[[@CR5]\].

To address this issue, a novel imaging modality, quantitative ultrashort time-to-echo, contrast enhanced (QUTE-CE) MRI \[[@CR6]\] was used to study changes in blood--brain barrier in the BBZDR/Wor rat an inbred rat strain model of type 2 diabetes \[[@CR7]\]. QUTE-CE MRI utilizes Ultrashort-Time-to-Echo (UTE) sequences with ferumoxytol, an FDA-approved superparamagnetic iron oxide nanoparticles (SPIONs) formula already used off-label for human MRI, as a contrast agent to produce positive contrast angiograms with low error of quantification \[[@CR6], [@CR8]\].

Research design and methods {#Sec2}
===========================

Animals {#Sec3}
-------

This study used male Bio-Breeding Zucker diabetic rats (BBZDR/Wor rats) (n = 8) and age-matched non-diabetic BBDR littermates (n = 7). The founding population was established by Biomere (Worcester, MA). The company decided to retire the breeding line and made a gift of their last animals to the Center for Translational NeuroImaging. The obese male BBZDR/Wor rat spontaneously develops type 2 diabetes at approximately 10 weeks of age (\~ 100%) when fed standard rat chow. BBZDR/Wor diabetic rat displays all clinical symptoms typically associated with type 2 diabetes including dyslipidemia, hyperglycemia, insulin resistance, and hypertension \[[@CR7]\],

Rats were maintained on a 12 h:12 h light--dark cycle with a light on at 07:00 h, allowed access to food and water ad libitum and were treated with intraperitoneal injections of saline at indications of weight loss. All animal experiments were conducted in accordance with the Northeastern University Division of Laboratory Animal Medicine and Institutional Animal Care and Use Committee. (<https://academic.oup.com/ilarjournal/article/45/3/292/704910>).

Access to rats was dependent upon the breeding schedule and resulting genotypes. This required we run two separate imaging studies, each with four rats from each genotype, separated by 6 months.

Imaging {#Sec4}
-------

Studies were done on a Bruker Biospec 7.0 T/20 cm USR horizontal magnet (Bruker, Billerica, MA, USA) and a 20-G/cm magnetic field gradient insert (ID = 12 cm) capable of a 120 μs rise time. Radio frequency signals were sent and received with a quadrature volume coil built into the rat restrainer (Animal Imaging Research, Holden, Massachusetts). All rats imaged under 1--2% isoflurane while keeping a respiratory rate of 40--50 breadths/min. At the beginning of each imaging session, a high-resolution anatomical data set was collected using the RARE pulse sequence with following parameters, 35 slice of 0.7 mm thickness; field of view 3 cm; 256 × 256; repetition time \[TR\] 3900 ms; effective echo time \[TE\] 48 ms; number of excitations 3; 6 min 14 s acquisition time.

Rats were imaged prior to and following an i.v. bolus of 6 mg/ml Fe of Ferumoxytol. The injected volume was tailored for each rat (assuming 7% blood by body weight) to produce a starting blood concentration of 200 μg/ml Fe (2 × the clinical dose approved for use in humans). The QUTE-CE MRI image parameters of TE = 13 µs, TR = 4 ms, and flip angle = 20° utilized a high radio frequency pulse bandwidth of 200 kHz. Therefore, the pulse duration was short (6.4 µs) compared to the T2 of the approximate ferumoxytol concentration (4.58 ms for 3.58 mM, i.e. 200 µg/ml to minimize signal blur and reduce the probability for a curved trajectory of the magnetization vector Mz. A 3 ×3×3 cm^3^ field-of-view was used with a matrix mesh size of 180× 180×180 to produce 167 µm isotropic resolution.

Images were motion-corrected, aligned spatially, and resliced using MATLAB SPM12 toolbox developed at UCL (<https://www.fil.ion.ucl.ac.uk/spm/>). The pre-contrast UTE images were set as the baseline. For each rat in each imaging session, the voxel wise percentage change of signal intensity was calculated as (post-con -- baseline)/(blood intensity change) \*100% as described in our previous work \[[@CR10]\], where blood intensity change is a normalization factor calculated by the post-con blood signal intensity minus baseline blood signal intensity. A 173-region rat brain atlas (Ekam Solutions LLC, Boston, MA, US) was fit to T2-weighted RARE anatomical data set for each rat data set taken at each imaging session, using software developed at Northeastern University Center for Translational Neuroimaging (CTNI), considering the variations in brain size and positions. The fitted atlas was transferred to UTE imaging. Once the images were co-registered to the atlas, custom MATLAB code was used to mask individual brain regions for ferumoxytol measurement. Post contrast UTE images are shown for a control and diabetic rat in Additional file [1](#MOESM1){ref-type="media"}: Figure S1.

Mode of percentage change distribution for each of the 173 brain areas for control and BBZDR/Wor rats was statistically compared using a Wilcoxon rank-sum test with the alpha set at 0.05. Data was analyzed by co-authors Cai and Kulkarni blind to the identity of the groups.

Data and resource availability {#Sec5}
------------------------------

All data can be accessed through a link to Mendeley. DOI to follow.

Results {#Sec6}
=======

Table [1](#Tab1){ref-type="table"} shows all the brain areas (147/173) that were significantly different (α p \< 0.05) in blood--brain barrier permeability between BBZDR/Wor rats and their littermate controls. Note in all cases BBZDR/Wor rats showed greater permeability. The location of these areas can be are visualized in the surrounding 2D and 3D images generated with the rat MRI atlas shown in Fig. [1](#Fig1){ref-type="fig"}. All areas in red in the 2D representations show significantly greater blood--brain barrier permeability in the BBZDR/Wor rats as compared to controls. Table [2](#Tab2){ref-type="table"} shows all brain areas (26/173) that were not significantly different in blood--brain barrier permeability between BBZDR/Wor rats and their littermate controls. These areas shown in white are localized to the prefrontal ctx, midbrain and cerebellum. These nonaffected areas are coalesced into 3D volumes and pictured in the glass brain in yellow.Table 1Brain areas that have significantly greater blood--brain barrier permeability in the diabetic BBZDR/Wor rat as compared to wild type controlsAreas with significant changes in blood--brain barrier permeabilityBrain areaControlDiabetes*P* valueMeanSDMeanSDParafascicular thalamic nucleus0.030.00 \< 0.080.010.000Visual 1 ctx0.030.00 \< 0.080.010.000Entorhinal ctx0.030.01 \< 0.090.010.000Dentate gyrus ventral0.030.01 \< 0.100.010.000Medial geniculate0.030.00 \< 0.110.010.000Medial dorsal thalamic nucleus0.020.00 \< 0.080.010.000Visual 2 ctx0.030.00 \< 0.090.010.000Vuditory ctx0.030.00 \< 0.080.010.000Ventral posteriolateral thalamic nucleus0.030.00 \< 0.070.010.000Triangular septal nucleus0.020.01 \< 0.070.010.000Bed nucleus stria terminalis0.010.00 \< 0.050.010.000Inferior colliculus0.040.01 \< 0.110.020.000Posterior thalamic nucleus0.030.00 \< 0.070.010.000Dorsal lateral striatum0.020.00 \< 0.060.010.000Lateral posterior thalamic nucleus0.030.01 \< 0.090.010.000Reticular nucleus0.030.00 \< 0.070.010.000CA1 dorsal0.030.00 \< 0.060.010.000Dentate gyrus dorsal0.030.00 \< 0.080.010.000Central amygdaloid nucleus0.010.01 \< 0.050.010.000Ventral lateral striatum0.020.00 \< 0.060.010.000Reuniens nucleus0.030.00 \< 0.070.010.000Globus pallidus0.020.00 \< 0.050.010.000Lateral geniculate0.040.01 \< 0.090.010.000Dorsal medial striatum0.020.00 \< 0.060.010.000Paraventricular nucleus0.030.00 \< 0.070.010.000Retrosplenial caudal ctx0.030.01 \< 0.120.020.000Lateral septal nucleus0.020.00 \< 0.060.010.000CA20.030.00 \< 0.060.010.000Ventrolateral thalamic nucleus0.030.00 \< 0.070.010.000External plexiform layer0.070.01 \< 0.120.010.000Periaqueductal gray thalamus0.040.00 \< 0.080.010.000Temporal ctx0.030.01 \< 0.120.020.000Ventral subiculum0.040.00 \< 0.080.010.000Ventral posteriomedial thalamic nucleus0.030.00 \< 0.080.010.000Basal amygdaloid nucleus0.010.01 \< 0.060.010.000Ventromedial thalamic nucleus0.030.00 \< 0.080.010.000Parietal ctx0.030.00 \< 0.060.010.000Caudal piriform ctx0.030.00 \< 0.080.020.000Medial amygdaloid nucleus0.030.01 \< 0.090.020.000CA1 hippocampus ventral0.040.01 \< 0.080.010.000Primary somatosensory ctx barrel field0.030.00 \< 0.070.010.000Zona incerta0.040.01 \< 0.080.010.000Primary somatosensory ctx forelimb0.020.00 \< 0.060.010.000Granular cell layer0.060.01 \< 0.100.010.000Habenula nucleus0.060.01 \< 0.150.030.000Primary somatosensory ctx trunk0.030.00 \< 0.060.010.000Lateral hypothalamus0.040.00 \< 0.080.020.000Primary somatosensory ctx shoulder0.020.01 \< 0.060.010.000Ventral medial striatum0.020.00 \< 0.050.010.000Glomerular layer0.090.01 \< 0.140.020.000Prerubral field0.040.01 \< 0.080.010.000Extended amygdala0.020.00 \< 0.050.010.000Anterior hypothalamic area0.020.00 \< 0.060.010.000Primary motor ctx0.020.00 \< 0.060.010.000Secondary somatosensory ctx0.030.00 \< 0.070.010.000Intercalated amygdaloid nucleus0.010.01 \< 0.070.010.000Primary somatosensory ctx upper lip0.030.00 \< 0.070.010.000White matter rostral0.030.00 \< 0.060.010.000CA3 dorsal0.030.00 \< 0.060.010.000Posterior hypothalamic area0.040.01 \< 0.100.020.000Central medial thalamic nucleus0.040.00 \< 0.070.010.000Dorsal raphe0.040.01 \< 0.080.010.000Supramammillary nucleus0.050.01 \< 0.150.040.000Primary somatosensory ctx hindlimb0.030.00 \< 0.060.010.000Ventral anterior thalamic nucleus0.030.01 \< 0.070.010.000Lateral amygdaloid nucleus0.030.01 \< 0.070.010.000Claustrum0.020.00 \< 0.050.010.000Perirhinal ctx0.050.01 \< 0.120.020.000Lateral dorsal thalamic nucleus0.030.01 \< 0.060.010.000Dorsal medial nucleus0.030.01 \< 0.070.010.000Ectorhinal ctx0.040.01 \< 0.150.050.000Olivary nucleus0.050.01 \< 0.090.020.000Copula of the pyramis0.070.01 \< 0.110.020.000Motor trigeminal nucleus0.040.01 \< 0.070.010.000Paramedian lobule0.060.00 \< 0.080.010.000Solitary tract nucleus0.030.01 \< 0.060.010.000Parvicellular reticular areas0.040.00 \< 0.060.010.000Precuniform nucleus0.040.01 \< 0.070.010.000Anterior cingulate area0.030.00 \< 0.080.020.000Cortical amygdaloid nucleus0.050.01 \< 0.100.020.000Primary somatosensory ctx jaw0.030.01 \< 0.060.010.000Parabrachial nucleus0.050.01 \< 0.080.010.000Principal sensory nucleus trigeminal0.050.00 \< 0.070.010.000Sub coeruleus nucleus0.040.00 \< 0.060.010.000White matter caudal0.040.00 \< 0.070.020.000Endopiriform nucleus0.020.01 \< 0.050.010.000Reticular nucleus midbrain0.040.01 \< 0.080.020.000Anterior thalamic nuclei0.030.01 \< 0.070.020.000Accumbens core0.020.01 \< 0.050.020.000Prelimbic ctx0.030.00 \< 0.060.020.0007th cerebellar lobule0.030.01 \< 0.060.010.000CA3 hippocampus ventral0.040.01 \< 0.080.020.000Ventral medial nucleus0.030.01 \< 0.080.030.000Dorsal paragigantocellularis0.030.01 \< 0.050.010.000Median raphe nucleus0.040.01 \< 0.060.010.000Pedunculopontine tegmental area0.040.01 \< 0.070.020.000Secondary motor ctx0.030.01 \< 0.070.020.000Central gray0.050.00 \< 0.080.010.000Retrosplenial rostral ctx0.050.01 \< 0.110.030.001Subthalamic nucleus0.070.01 \< 0.110.020.001Medial preoptic area0.020.01 \< 0.050.010.001Medial septum0.030.01 \< 0.060.010.001Gigantocellularis reticular nucleus pons0.030.00 \< 0.050.010.001Superior colliculus0.040.01 \< 0.070.020.001Subiculum dorsal0.040.00 \< 0.060.010.001Lateral preoptic area0.020.01 \< 0.050.020.001Magnocellular preoptic nucleus0.030.01 \< 0.080.030.001Dorsomedial tegmental area0.040.01 \< 0.060.020.001Neural lobe pituitary0.140.05 \< 0.260.060.001Medial cerebellar nucleus fastigial0.060.01 \< 0.080.010.001Substantia nigra compacta0.050.01 \< 0.100.030.0018th cerebellar lobule0.040.01 \< 0.060.010.001Medial mammillary nucleus0.070.04 \< 0.200.080.002Pontine reticular nucleus caudal0.030.00 \< 0.050.010.002Flocculus cerebellum0.050.01 \< 0.080.020.002Substantia nigra reticularis0.070.02 \< 0.120.030.002Supraoptic nucleus0.050.01 \< 0.080.020.002Reticulotegmental nucleus0.030.01 \< 0.050.010.003Anterior lobe pituitary0.170.02 \< 0.280.070.003Accumbens shell0.030.01 \< 0.060.020.003Inferior olivary complex0.050.00 \< 0.070.020.00310th cerebellar lobule0.070.01 \< 0.090.010.003Infralimbic ctx0.030.01 \< 0.070.020.003Cochlear nucleus0.060.01 \< 0.080.020.004Premammillary nucleus0.050.02 \< 0.110.040.004Insular ctx0.040.01 \< 0.070.020.004Red nucleus0.050.01 \< 0.080.020.004Suprachiasmatic nucleus0.010.02 \< 0.050.020.005Root of trigeminal nerve0.050.00 \< 0.070.020.005Interposed nucleus0.060.01 \< 0.080.010.006Vestibular nucleus0.050.01 \< 0.060.010.0069th cerebellar lobule0.050.01 \< 0.070.010.0072nd cerebellar lobule0.070.01 \< 0.100.020.007Pontine reticular nucleus oral0.040.01 \< 0.050.010.008Retrochiasmatic nucleus0.050.04 \< 0.130.060.009Anterior pretectal nucleus0.030.00 \< 0.070.030.009Trapezoid body0.030.01 \< 0.060.020.010Facial nucleus0.050.01 \< 0.070.020.010Raphe obscurus nucleus0.030.01 \< 0.040.010.011Ventral pallidum0.040.01 \< 0.070.020.011Raphe linear0.060.01 \< 0.080.020.012Periolivary nucleus0.050.02 \< 0.080.030.019Dentate n. cerebellum0.050.01 \< 0.060.020.019Arcuate nucleus0.070.04 \< 0.130.060.023Substantia innominata0.050.02 \< 0.090.030.024Paraflocculus cerebellum0.060.01 \< 0.070.020.026Anterior amygdaloid nucleus0.030.01 \< 0.050.030.035Areas are ranked in order of their significance (α \< 0.05). False detection rate (α = 0.17)Fig. 1Imaging blood brain barrier permeability. Quantitative ultra-short time-to-echo, contrast enhanced imaging of blood brain barrier permeability comparing BBZDR/Wor rats and their littermate controls. All areas in red show significantly greater permeability in type 2 diabetic as compared to controlsTable 2Brain areas that show no significant differences in blood--brain barrier permeability in the diabetic BBZDR/Wor rat as compared to wild type controlsAreas with nonsignificant changes in blood--brain barrier permeabilityBrain areaControlDiabetesMeanSDMeanSD*P*valueOlfactory tubercles0.070.02 \< 0.100.040.067Medial pretectal area0.000.16 \< 0.170.180.070Raphe magnus0.030.01 \< 0.050.020.088Paraventricular nucleus0.060.02 \< 0.090.050.0913rd cerebellar lobule0.070.01 \< 0.090.030.110Ventral tegmental area0.070.02 \< 0.110.060.130Rostral piriform ctx0.050.02 \< 0.070.030.143Locus coeruleus0.070.01 \< 0.080.010.146Diagonal band of Broca0.040.02 \< 0.060.030.157Ventral orbital ctx0.040.01 \< 0.060.030.1666th cerebellar lobule0.040.01 \< 0.050.010.200Lateral orbital ctx0.040.01 \< 0.060.030.285Anterior olfactory nucleus0.050.01 \< 0.070.040.289Tenia tecta ctx0.060.02 \< 0.090.060.2901st cerebellar lobule0.050.01 \< 0.060.020.353Simple lobule cerebellum0.090.01 \> 0.070.050.423Pontine nuclei0.050.03 \< 0.070.050.451Pineal gland0.860.04 \< 0.900.120.458Interpeduncular nucleus0.090.04 \< 0.110.080.522Medial orbital ctx0.090.01 \> 0.080.050.526Crus 2 of ansiform lobule0.060.000.060.010.604Lemniscal nucleus0.060.02 \< 0.070.030.611Frontal association ctx0.080.010.080.040.658Crus 1 of ansiform lobule0.060.01 \> 0.050.020.7904th cerebellar lobule0.070.010.070.040.8095th cerebellar lobule0.070.01 \> 0.060.040.856Areas are ranked in order of their *P* values

Discussion {#Sec7}
==========

QUTE-CE MRI, was developed as a quantitative vascular biomarker \[[@CR6]\]. Ferumoxytol (Feraheme™) MRI with optimized 3D Ultra-Short Time-to-echo (UTE) Pulse Sequences produces angiographic images unparalleled to time-of-flight imaging or gadolinium-based first-pass imaging. The contrast agent is ferumoxytol, an ultra-small superparamagnetic iron oxide nanoparticle with a dextran coating. Since the size exceeds the cutoff (\~ 6 nm) for glomerular filtration, ferumoxytol is not cleared by the kidney, and instead is an excellent blood pool contrast agent with a long intravascular half-life of \~ 15 h \[[@CR9]\]**.** Numerous clinical MRI studies using ferumoxytol have been conducted in children and adults, demonstrating no major adverse effects, thus QUTE-CE can be readily used in the clinic to study blood--brain barrier permeability \[[@CR10]\]. We recently published a study mapping the absolute physiological cerebral blood volume (CBV) of the awake rat brain, including measurements of microvasculature density and vascular functional reserve \[[@CR8]\]. QUTE-CE MRI can be used for identifying hyper- or hypo-vascularization, small vessel density, blood--brain barrier permeability and vascular reserve and vascular responsivity to CO2 challenge at the individual voxel and regional levels using our rat 3D MRI atlas. As demonstrated in this study with the BBZDR/Wor rats, a preclinical model of type 2 diabetes, this imaging technology could be used to diagnose and evaluate blood brain permeability and disease progression in diabetic encephalopathy in the clinic.

Limitations and future directions {#Sec8}
=================================

As a pilot study with a small population of rats there were several limitations: (1) Females were not studied. Unfortunately, only males develop diabetes in the BBZDR/Wor strain of rats \[[@CR7]\]. (2) While the blood--brain permeability was pervasive in this late-stage model of diabetes and not unexpected, postmortem histology would have confirmed the capillary pathology and helped to understand why areas like the cerebellum and midbrain were spared. (3) In the future, a thorough comparison between DCE and QUTE-CE should be done to provide quantitative data on the differences and similarities between both imaging techniques. (4) More common rat models of T2DB should be tested like the Goto-Kakizaki GK rat \[[@CR11]\] or high-fat diet, streptozotocin treated Wistar rat (HFD/STZ) \[[@CR12]\].

Conclusion {#Sec9}
==========

Small vessel disease as assessed by permeability in the blood--brain barrier in type 2 diabetes is pervasive and includes much of the brain. The increase in blood--brain barrier permeability is a likely contributing factor to diabetic encephalopathy and dementia.

Supplementary information
=========================

 {#Sec13}

**Additional file 1: Figure S1.** Shown are raw data from a control and diabetic rat following ferumoxytol injection. The normalized UTE signal is registered to the original anatomy.
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